Beyond Air, Inc. · NASDAQ:XAIR
Beyond Air — Investor Presentation (March 2020)
56 slides from Beyond Air's investor presentation, Mar 31, 2020
Slide 1: Corporate Presentation April 2020
Corporate Presentation 6& Beyond Air- April 2020 The Magic of Breathing
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities of Beyond Air, Inc. (the “Company”) nor shall there be any sale of securities in any
Slide 3: LungFit generator generates NO from ambient air, eliminating cylinders
Beyond Air’s LungFit™ generator and delivery system generates NO from ambient air, eliminating the need for expensive and cumbersome cylinders Beyond Air's system provides significant advantages over approved NO cylinder based systems currently used in hospitals around the world AND may allow for us
Slide 4: Program milestones 1H20 to 2H21
ProgramPr 1H20 2H20 1H21 2H21 LungFit™ PH Pulmonary Hypertension (PPHN & Heart Submit PMA to US FDA Continue to launch globally Continue to launch globally Surgery?) LungFit™ COVID-19 e e LungFit™ Report data from Pilot Pivotal study initiation Begin pivotal study in Bronchiolitis Study in Israel de
Slide 5: Nitric Oxide is Naturally Occurring in the Human Body
Nitric Oxide (NO) is Naturally Occurring in the Human Body") Antibacterial Apoptosis Cell proliferation Angiogenesis Immune response Neurotransmission Cardiovascular homeostasis ba Beyond Air (1) Bian K & Murad F. Nitric Oxide, (2014) | Bodgan C. Trends in Immunol, (2015) The Magic of Breathing
Slide 6: NO Already Plays a Major Role in the Human Immune System
NO Already Plays a Major Role in the Human Immune System Functions of NO e immune system Macrophages, microglia, neutrophils, eosinophils, fibroblasts, endothelial cells, epithelial cells Antimicrobial activity Killing or reduced replication of infectious agents (viruses, bacteria, protozoa, fungi a
Slide 7: LungFit: The Magic of Breathing
LungFit™: The Magic of Breathing Nitric Oxide (NO) ee ee LungFit BRO baBeyond Air i 6& Beyond Ai ir The Magh hing
Slide 8: Beyond Air: Active Pipeline
Beyond Air: Active Pipeline Worldwide ee Development ; US Sales Indication Key Dates ae Sales Status Potential® = 12) Potential LungFit™ PH In-Hospital use Final preparations PMA filing 2020 (Pulmonary for PPHN and for PMA >$300 million >$600 million Hypertension) cardiac surgery submission US Launc
Slide 9: LungFit PH
LungFit’ PH Cylinder Free NO Delivery for Persistent Pulmonary Hypertension of the Newborn (PPHN) LingFt PH 6&Beyond Air
Slide 10: First Indication: Pulmonary Hypertension Overview
First Indication: Pulmonary Hypertension (PH) Overview NO is an established therapeutic option for patients suffering from Pulmonary Hypertension worldwide Pulmonary Hypertension Overview Effects of Pulmonary Hypertension” = Life-threatening condition from increased pulmonary . - vascular resistance
Slide 11: NO is an established therapeutic option for Pulmonary Hypertension
NO is an established therapeutic option for patients suffering from Pulmonary Hypertension 1% competitor entered >$500M revenue market Q4 2019 market) ~8% CAGR 2014-2019 (0) ~800 hospitals use NO ©) Potential label 2 ‘ expansion to ~ q) 5 systems per hospital include pediattic cardiovascular patient
Slide 12: LungFit PH: Next generation NO care for patients worldwide
LungFit™ PH: Next generation NO care for patients worldwide LungFit PH Cylinder Free Nitric Oxide Therapeutic Platform * Designed for the treatment of pulmonary hypertension for certain ventilated patients, dependent on approvals in each country, in the hospital setting(1) ° Width: ~24 inches ° Dept
Slide 13: LungFit: Versus Hospital Standard of Care
LungFit™: Versus Hospital Standard of Care Smart Height 45" 125° Width 15? 2.63" Depth NA 1.88” Weight 45 Ibs 2.5 02. oe LungFit™ Engi Height ~60" 15° 60" Width ~=20" 18" 24" Depth ~21" 14” 28" Weight 175 Ibs 32 Ibs 65 Ibs BABeYONM AI creoe snare enn On ney otra tt os mete The Magic of Breathing BAB
Slide 14: LungFit PH: Next generation NO care for patients worldwide
LungFit™ PH: Next generation NO care for patients worldwide * Don’t want the cart? NO problem! * Detachable Unit (weight ~32 Ibs) LungFit PH ALARMS. MARSPORI. FRTERTIME: 109 3 BATT DOM 02% | NO2(ppm) | NO(ppm) | “ER” 22 0.5 20 18 100 30 15 25 User Interface ba ele Air BA Beyond Aire cater. snrmisen
Slide 15: Losing the High-Pressure Cylinder is a significant gain
Losing the High-Pressure Cylinder is a significant gain Hospitals will have si ant cost, safety & logistics advantages Improved operating economics for the hospital No significant capital investment required for hospitals new to NO No burdensome inventory and storage requirements Reduced training bu
Slide 16: Beyond Air: Active Pipeline
Beyond Air: Active Pipeline Worldwide Seu Development : US Sales Indication Key Dates) cae Sales Status Potential® AaB Potential® LungFit™ PH In-Hospital use Final preparations PMA filing 2Q20 (Pulmonary for PPHN and for PMA >$300 million >$600 million Hypertension) cardiac surgery submission US Lau
Slide 17: COVID-19 LungFit Potential: Safe, Efficacious, Practical
Slide 18: High Concentration NO Delivery Has a Demonstrated Safety Record
High Concentration NO Delivery Has a Demonstrated Safety Record in People and Animals with XAIR Technology * Rats: 30 days of intermittent treatments with LungFit™ at 400 ppm NO showed no macroscopic or microscopic findings © Rats: 12 weeks of intermittent treatments with LungFit™ at 250 ppm NO show
Slide 19: Nitric Oxide Mechanism of Action (MOA)
Nitric Oxide Mechanism of Action (MOA) ¢ Nitric Oxide has multiple MOA‘s —Bronchodilator — Anti-inflammatory —Viral Elimination ¢ Anti-Inflammatory: —Immunoregulatory functions Inhibition of T and B cell proliferation, leukocyte recruitment (adhesion, extravasation, chemotaxis), Antibody production
Slide 20: NO Inhibits the Replication Cycle of SARS Coronavirus
NO Inhibits the Replication Cycle of Severe A Respiratory Syndrome (SARS) Coronavirus JOURNAL OF VIROLOGY, Feb. 2005, p. 1966-1969 Vol. 79, No. 3 0022-538X/05/S08.00+0 doi:10.1128/JVI.79.3.1966-1969.2005 Copyright © 2005, American Society for Microbiology. All Rights Reserved. Nitric Oxide Inhibits
Slide 21: LungFit: A Practical Solution for COVID-19
LungFit™: A Practical Solution for COVID-19 Generated from Ambient Air, use it anywhere! ° Easy to Use: * Programmable by filter * Convenient for all ¢ Use with any electrical outlet LungFit BRO \ * Pormabie \ ° Width 11 inches, Depth 16 inches, Height 10 inches, Weight ~20 Ibs * One system can trea
Slide 22: COVID-19: What is Beyond Air Doing Now?
COVID-19: What is Beyond Air Doing Now? * Inthe lab ¢ BSL level 2+ in Israel * Testing other types of human coronavirus * Moving to BSL level 3 (necessary to test SARS-CoV-2) * Anticipated completion of level 3 lab April/May 2020 * Exploring opportunities to test SARS-CoV-2 in 3" party labs * In hum
Slide 23: Beyond Air: Active Pipeline
Beyond Air: Active Pipeline Saco Development : US Sales Worldwide Indication Key Dates( a Sales Status Potential®) : Potential® LungFit™ PH In-Hospital use Final preparations PMA filing 2Q20 (Pulmonary for PPHN and for PMA >$300 million >$600 million Hypertension) cardiac surgery submission US Launc
Slide 24: LungFit BRO
LungFit BRO High Concentration Nitric Oxide Delivery for Bronchiolitis
Slide 25: Bronchiolitis Overview & Market Dynamics
Bronchiolitis Overview & Market Dynamics * ~130,000 infant hospitalizations per year in the US@ * Significant impact on the elderly with 177,000 hospitalizations per year in the US®) for RSV alone « No drugs approved for the treatment of BRO patients * Standard of care in the hospital is oxygen and
Slide 26: Bronchiolitis (BRO) Overview
Bronchiolitis (BRO) Overview A leading cause of global child mortality Bronchiolitis overview * Bronchiolitis is an acute inflammatory injury of the bronchioles usually caused by a viral infection. BRONCHITIS inflammation and swelling of the bronchi Effects of Bronchiolitis® * Bronchiolitis usually
Slide 27: LungFit BRO Profile
LungFit™ BRO Profile * Simple, Safe, Practical | * 150ppm concentration * 4 daily treatments each 40 minutes apart LungFit BRO + Intuitive interface * Simple system ¢ Breathing circuit * Sample line ° Filter * Portable: Width 11 inches, Depth 16 inches, Height 10 inches, ; Weight ~20 Ibs 7 "Caution
Slide 28: Completed Two Pilot Bronchiolitis Trials
Completed Two Pilot Bronchiolitis Trials 2018 Trial Design and Baseline Characteristics Data Presented at the September 2018 * Randomized 67 subjects at 6 sites in Israel with a 1:1 European Respiratory Society (ERS) randomization between 160 ppm NO + supportive care (O2 + hydration) and supportive
Slide 29: Completed Two Pilot Bronchiolitis Trials
Completed Two Pilot Bronchiolitis Trials Data from both Pilot Bronchiolitis trials demonstrated a significant reduction in LOS 2018 Trial Results Presented at ERS 2018 Length of Stay (Per-protocol) $p02292% (Per-protocol) 20.848.9 hr 26.7412.7 hr 0.023) (p=0.04) ~ ae * Secondary endpoint of aa La ti
Slide 30: Pivotal LungFit BRO: Bronchiolitis Study
Pivotal LungFit™ BRO: Bronchiolitis Study Protocol Summary uble blind randomized placebo controlled pivotal study - Approximately 265 subjects < 12 months of age hospitalized with acute bronchiolitis — Potential for a reduction in # of subject dependent on results from ongoing study in Israel (data
Slide 31: Beyond Air: Active Pipeline
Beyond Air: Active Pipeline Worldwide Seu Development : US Sales Indication Key Dates) cae Sales Status Potential® AaB Potential® LungFit™ PH In-Hospital use Final preparations PMA filing 2Q20 (Pulmonary for PPHN and for PMA >$300 million >$600 million Hypertension) cardiac surgery submission US Lau
Slide 32: LungFit NTM
LungFit' NTM High Concentration Nitric Oxide Delivery for Nontuberculous Mycobacteria (NTM)
Slide 33: LungFit: Let's Bring it HOME!
LungFit™: Let's Bring it HOME! Simple, Safe, Small & Super LungFit NTM Plug It In nity [x] , Ny, ” , Ses _ Press Go SE 92 TunitOn —»> Place Mask on Face Insert Filter BA Beyond Air cesten- snes ex esier Oe inte eter ttt 9 an mest se 33 ‘The Magic of Breathing
Slide 34: LungFit: Let's Bring it ANYWHERE!
LungFit™: Let's Bring it ANYWHERE! | All You Need is a Standard Electrical Outlet Cale b& Beyond Air 34 ‘The Magic of Breath
Slide 35: Home Market: Nontuberculous Mycobacteria (NTM)
Home Market: Nontuberculous Mycobacteria (NTM) NTM is an FDA disease area of focus with limited options. Patients can die within a few years(1) NTM Market Dynamics? Over 180k NTM cases were estimated for 2014 in the United States There are a limited number of players in NTM Beyond Air is targeting N
Slide 36: Pulmonary Infections: e.g. NTM
Pulmonary Infections: e.g. Nontuberculous Mycobacteria (NTM) * Exogenous Nitric Oxide demonstrates a dose response effect S 10% ‘ against M. abscessus in vitro. Significant bacterial killing (>3-log FA © Control (air) alll Q 10 reduction) is observed at 250ppm NO é -® NO (160ppm) H 105 ~~ NO(250ppm)
Slide 37: Pulmonary Infections: e.g. NTM
Pulmonary Infections: e.g. Nontuberculous Mycobacteria (NTM) NO shows synergy with clofa ine and amikacin against drug-resistant M. abscessus in NO synergistic effect seen with clofazimine (CLO) and NO + CLO (M. abscessus ATCC 19777) amikacin (AMI): Each drug in Kruskal-Wallis (p=0.0059) combination
Slide 38: Home Market: Nontuberculous Mycobacteria (NTM)
Home Market: Nontuberculous Mycobacteria (NTM) a single arm pilot NTM study with 160 PPM Mean change in 6MW Distance (meters) from Baseline Mean change in FEV1 from Baseline 2 iNO Therapy Off Therapy 2 iNO Therapy Off Therapy gs 3 Sx ga ei ra} en — 3 = = Po os = @ D> @ 4 = Se Sw © 8 Ss os @ x - @ &
Slide 39: Pilot LungFit NTM Study Protocol Summary
Pilot LungFit™ NTM Study Protocol Summary Open label pilot study with 12 weeks of treatment and 12 weeks of observation * Approximately 20 subjects > 18 years of age with NTM lung infection refractory to antibiotic therapy — Both MAC (Mycobacterium avium complex) and Mabs (Mycobacterium abscessus co
Slide 40: Beyond Air: Active Pipeline
Beyond Air: Active Pipeline Worldwide Seu Development : US Sales Indication Key Dates) cae Sales Status Potential® AaB Potential® LungFit™ PH In-Hospital use Final preparations PMA filing 2Q20 (Pulmonary for PPHN and for PMA >$300 million >$600 million Hypertension) cardiac surgery submission US Lau
Slide 41: LungFit NTM: High Concentration NO Delivery for COPD Exacerbations
LungFit' NTM High Concentration Nitric Oxide Delivery for COPD Exacerbations
Slide 42: How Big is the HOME Market for Severe Lung Infections?
How Big is the HOME Market for Severe Lung Infections? sais the largest at-risk population for opportunistic lung infections There are an estimated 30m people in the US suffering from COPD" with 10% considered severe®) 6& Beyond Air The Magic of Breathing Data from 2010 Show? + 1,075,575 estimated a
Slide 43: Continuous nitric oxide antiviral data
1.010". - : 10x10" 1.0108 1.010% 1.010% CFU\mL CFU\mL 1.010% 1.0«10" 1.010%. ‘ r 0.0 Continuous nitric oxide 40ppm and 80ppm Continuous nitric oxide160ppm and 800ppm 150 x0 Control -® contol ag “*— 40ppm NO Laid —t— 160ppm NO PFU'sim! = 80ppm NO ence —¥= 800ppm NO 200 400 40 400 50 3 or 0 . 7 2 3s @
Slide 44: COPD Exacerbations Due to opportunistic infections
COPD Exacerbations Due to opportunistic infections from a variety of pathogens # Pathog Percentage of patients Ref. 1 Haemophilus influenzae 13%-50% (11, (21 2 Moraxella catarrhalis 9-21% (2) 3 Streptococcus pneumoniae 7-26% (11, (2 4 Rhinovirus 4-29% (11. Bl 5 Influenza virus 16% (1 6 Staphylococcu
Slide 45: Beyond Air: Active Pipeline
Beyond Air: Active Pipeline Worldwide Seu Development : US Sales Indication Key Dates) cae Sales Status Potential® AaB Potential® LungFit™ PH In-Hospital use Final preparations PMA filing 2Q20 (Pulmonary for PPHN and for PMA >$300 million >$600 million Hypertension) cardiac surgery submission US Lau
Slide 46: Gaseous Nitric Oxide for Solid Tumors
Gaseous Nitric Oxide for Solid Tumors
Slide 47: NO is a Powerful Anti-Cancer Agent, But How Powerful?
NO is a Powerful Anti-Cancer Agent, But How Powerful? ¢ NO has been reported to show anticancer properties at high concentrations ¢ At high concentrations, NO induces DNA damage, and as a result, p53 is upregulated, leading to cell growth arrest and apoptosis * Tumor regression * Oxidative and nitro
Slide 48: The effect of gaseous NO on different cancer cell lines in-vitro
The effect of gaseous NO on different cancer cell lines in-vitro Data to be presented at the American Association for Cancer Research (AACR) April 24-29 POSTPONED DUE TO COVID-19 PANDEMIC >70 mice studied
Slide 49: Can Safety Be Maintained for Patients and Caregivers?
Can Safety Be Maintained for Patients and Caregivers? e Miniature Cylinder for single dose ¢ Small amount maintains safety in case of premature NO release ° Easy to handle ° Easy to transport ° Proprietary delivery systems developed * Optimization of system ongoing ° Patents filed 6A Beyond Air 49
Slide 50: Additional Information
Additional Information 6A Beyond Air
Slide 51: Issued Patents and Pending Patents Across Major Global Markets
>20 Issued Patents and >10 Pending Patents Across Major Global Markets
Slide 52: Financial Portfolio
Financial Portfolio Ticker XAIR Exchange NASDAQ Sila Share Price (as of March 26, 2020) Shares “he ae eondine 15.5 million Cash & Marketable $15 million Securities Debt so Expected Monthly Burn is approximately $1M-1.1M Accessibility to Cash $20 million stock purchase agreement in place through Augu
Slide 53: Highly experienced and successful team of industry experts
Highly experienced and successful team of industry experts 18 years experience as a Healthcare investor DEERFIELD 3 years as SVP Head of Strategy and BD at Avadel (AVDL) = Previously worked in HC investments at SAC Capital, Millennium Management, and wy Avadel was a partner at Deerfield 15 years of
Slide 54: Board of Directors with vast industry experience
Board of Directors with vast industry experience 18 years experience as a Healthcare investor 3 years as SVP Head of Strategy and BD at Avadel (AVDL) DEERFIELD Previously worked in HC investments at SAC Capital, Millennium a Management, and was a partner at Deerfield » Avadel ° 15 years of executive
Slide 55: LungFit generator generates NO from ambient air, eliminating cylinders
Beyond Air’s LungFit™ generator and delivery system generates NO from ambient air, eliminating the need for expensive and cumbersome cylinders Beyond Air's system provides significant advantages over approved NO cylinder based systems currently used in hospitals around the world AND may allow for us
Slide 56: For more information
For more information 6a Beyond Air’ contact: Investor Relations IR@beyondair.net www.beyondair.net The Magic of Breathing f=) i / 6A Beyond Air Wiehe! rothing